Multiple Myeloma Licensing Deal Benchmarks

Median Upfront

$383M

Range: $213M - $542M

Total Deal Value

$2.4B

Range: $1.6B - $3.3B

Royalty Rate

13.3% - 21.7%

Tiered up to 25.7%

Dev Milestones

$512M

Range: $342M - $685M

Model Your Deal

Market Analysis

Multiple myeloma is among the most actively licensed hematologic indications, driven by a large and growing patient population and a well-defined treatment landscape with multiple lines of therapy. Phase 2 myeloma deals carry a median total deal value of $2.4B, with upfront payments between $213M and $542M.

Deal structures reflect the established development pathway in myeloma. Development milestones average $512M, while regulatory milestones contribute $819M and commercial milestones reach $717M. The overall structure splits approximately 16% upfront and 84% milestones.

Royalty rates for myeloma licensing agreements range from 13.3% to 21.7% at the base tier, escalating to 25.7% on high-volume sales. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 are commanding the highest valuations, followed by novel CAR-T approaches and next-generation immunomodulators.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are benchmark deal terms for multiple myeloma licensing?

Phase 2 myeloma deals average $383M upfront with $2.4B total deal value. The established development pathway and large addressable market support robust valuations across modalities.

Which modalities dominate myeloma licensing deals?

Bispecific antibodies and CAR-T cell therapies lead myeloma deal activity. BCMA-targeting agents remain most popular, with emerging interest in GPRC5D and FcRH5 targets. Next-generation CELMoDs and bispecific-CAR-T combinations are gaining traction.

How do myeloma deal terms vary by line of therapy?

First-line myeloma assets command 20-30% higher total deal values than relapsed/refractory (3L+) assets, reflecting the larger addressable population and longer duration of therapy. However, late-line assets with breakthrough data can rival first-line valuations.

What royalty rates are standard for myeloma licensing?

Base royalty rates of 13.3%-21.7% for myeloma deals are competitive with broader oncology benchmarks. Tiered royalties can reach 25.7% on peak sales, reflecting the multi-billion dollar commercial opportunity.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Multiple Myeloma Licensing Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

CAR-T Cell Therapy Deals

Bispecific Antibody Deals

Phase 2 Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?